D
Description
Swedish biotech headquartered in Uppsala (renamed Dicot Pharma in 2024). Develops LIB-01 (Libiguin), a compound derived from a folk medicinal plant for erectile dysfunction. Positive Phase 2 results showing sustained improvement over 8 weeks.